HK1201253A1 - Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof - Google Patents
Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof Download PDFInfo
- Publication number
- HK1201253A1 HK1201253A1 HK15101876.0A HK15101876A HK1201253A1 HK 1201253 A1 HK1201253 A1 HK 1201253A1 HK 15101876 A HK15101876 A HK 15101876A HK 1201253 A1 HK1201253 A1 HK 1201253A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- deuterium
- enriched
- perillyl alcohol
- alcohol
- iso
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/05—Alcohols containing rings other than six-membered aromatic rings
- C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Radiology & Medical Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562105P | 2011-11-21 | 2011-11-21 | |
| US61/562,105 | 2011-11-21 | ||
| US13/566,731 US8916545B2 (en) | 2010-08-27 | 2012-08-03 | Pharmaceutical compositions comprising POH derivatives |
| US13/566,731 | 2012-08-03 | ||
| PCT/US2012/066379 WO2013119304A2 (en) | 2011-11-21 | 2012-11-21 | Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1201253A1 true HK1201253A1 (en) | 2015-08-28 |
Family
ID=48948152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15101876.0A HK1201253A1 (en) | 2011-11-21 | 2012-11-21 | Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2782894A4 (enExample) |
| JP (2) | JP2015502352A (enExample) |
| KR (1) | KR20150000469A (enExample) |
| CN (1) | CN103946202A (enExample) |
| BR (1) | BR112014012180A2 (enExample) |
| CA (1) | CA2856403A1 (enExample) |
| HK (1) | HK1201253A1 (enExample) |
| WO (1) | WO2013119304A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104945334B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏醇衍生物及其制备和应用 |
| CN104945333B (zh) * | 2014-03-27 | 2018-02-02 | 沈阳药科大学 | 紫苏醇类似物及其制备和应用 |
| CN104945335B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏胺类化合物及其制备和应用 |
| CN104945336B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏酸甲酯含氮衍生物及其制备和应用 |
| JP7325425B2 (ja) * | 2018-02-08 | 2023-08-14 | ネオンク テクノロジーズ インク. | 血液脳関門を透過性にする方法 |
| CN116789530B (zh) * | 2023-05-16 | 2025-12-19 | 杭州师范大学 | 一种紫苏醇酚类衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272441A (en) * | 1980-03-13 | 1981-06-09 | Fmc Corporation | Preparation of carbamates |
| WO2002076404A2 (en) * | 2001-03-23 | 2002-10-03 | Protarga, Inc. | Fatty alcohol drug conjugates |
| US20060104997A1 (en) * | 2001-12-11 | 2006-05-18 | Constantinides Panayiotis P | Monoterpene compositions and uses thereof |
| BR0107262B1 (pt) | 2001-12-17 | 2014-04-22 | Da Fonseca Clovis Orlando Pereira | Composição farmacêutica inalatória |
| KR20070051258A (ko) * | 2004-06-23 | 2007-05-17 | 호프만 로버트 에프 | 표적화되는 산화적 치료 제형의 화상 치료에서의 용도 |
| US7601355B2 (en) | 2005-06-01 | 2009-10-13 | Northwestern University | Compositions and methods for altering immune function |
| EP2081565A2 (en) * | 2006-10-13 | 2009-07-29 | Reliance Life Sciences Pvt., Ltd. | Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer |
| WO2010091198A1 (en) * | 2009-02-06 | 2010-08-12 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| EP2898883B1 (en) * | 2010-08-27 | 2016-11-23 | Neonc Technologies Inc. | Pharmaceutical compositions comprising perillyl alcohol carbamates |
| CN101979378B (zh) * | 2010-10-13 | 2012-06-27 | 中国科学院上海有机化学研究所 | 一种手性γ-内酰胺化合物的合成方法 |
-
2012
- 2012-11-21 BR BR112014012180A patent/BR112014012180A2/pt not_active IP Right Cessation
- 2012-11-21 JP JP2014542593A patent/JP2015502352A/ja active Pending
- 2012-11-21 CA CA2856403A patent/CA2856403A1/en not_active Abandoned
- 2012-11-21 CN CN201280057166.6A patent/CN103946202A/zh active Pending
- 2012-11-21 KR KR20147016865A patent/KR20150000469A/ko not_active Withdrawn
- 2012-11-21 WO PCT/US2012/066379 patent/WO2013119304A2/en not_active Ceased
- 2012-11-21 EP EP12867815.8A patent/EP2782894A4/en not_active Withdrawn
- 2012-11-21 HK HK15101876.0A patent/HK1201253A1/xx unknown
-
2017
- 2017-08-24 JP JP2017161091A patent/JP2018035148A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018035148A (ja) | 2018-03-08 |
| WO2013119304A2 (en) | 2013-08-15 |
| BR112014012180A2 (pt) | 2017-05-30 |
| KR20150000469A (ko) | 2015-01-02 |
| JP2015502352A (ja) | 2015-01-22 |
| WO2013119304A3 (en) | 2013-10-03 |
| EP2782894A4 (en) | 2015-03-11 |
| CN103946202A (zh) | 2014-07-23 |
| EP2782894A2 (en) | 2014-10-01 |
| CA2856403A1 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012027693A3 (en) | Pharmaceutical compositions comprising poh derivatives | |
| WO2013119304A3 (en) | Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof | |
| PE20151005A1 (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| EP4374929A3 (en) | Methods and devices for using isoperillyl alcohol | |
| MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
| CR20140108A (es) | Compuesto de ciclopropanoamina | |
| CL2012001714A1 (es) | Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras. | |
| DOP2010000011A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
| CL2013000481A1 (es) | Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas. | |
| WO2014145642A3 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
| WO2016130800A3 (en) | Pharmaceutical compositions comprising perillyl alcohol derivatives | |
| MX383077B (es) | Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio. | |
| WO2012092421A3 (en) | Composition for intravascular delivery of therapeutic composition | |
| EP4613333A3 (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| CL2015001187A1 (es) | Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades. | |
| DOP2013000314A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| WO2011058245A8 (fr) | Nouveaux derives de mannopyranoside ayant une activite anticancereuse | |
| PE20150345A1 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo | |
| WO2012002773A3 (en) | Phenylcarbamate compound and muscle relaxant containing the same | |
| WO2015009742A3 (en) | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | |
| CO2019008657A2 (es) | Composición intranasal que comprende betahistina | |
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| WO2013037985A8 (en) | Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |